| Authors: |
Oldham RJ; Antibody and Vaccine Group, School of Cancer Sciences, University of Southampton, Southampton, UK., Mårtensson L; BioInvent, Lund, Sweden., Semmrich M; BioInvent, Lund, Sweden., Yoosuf N; BioInvent, Lund, Sweden., Holmkvist P; BioInvent, Lund, Sweden., Graham LV; Antibody and Vaccine Group, School of Cancer Sciences, University of Southampton, Southampton, UK., Taylor MC; Antibody and Vaccine Group, School of Cancer Sciences, University of Southampton, Southampton, UK., Cleary KLS; Antibody and Vaccine Group, School of Cancer Sciences, University of Southampton, Southampton, UK., Yazdani M; Antibody and Vaccine Group, School of Cancer Sciences, University of Southampton, Southampton, UK., Buckingham JF; Antibody and Vaccine Group, School of Cancer Sciences, University of Southampton, Southampton, UK., Roghanian A; Antibody and Vaccine Group, School of Cancer Sciences, University of Southampton, Southampton, UK., Karlsson I; BioInvent, Lund, Sweden., Beers SA; Antibody and Vaccine Group, School of Cancer Sciences, University of Southampton, Southampton, UK., Teige I; BioInvent, Lund, Sweden., Cragg MS; Antibody and Vaccine Group, School of Cancer Sciences, University of Southampton, Southampton, UK., Frendéus B; Antibody and Vaccine Group, School of Cancer Sciences, University of Southampton, Southampton, UK. bjorn.frendeus@bioinvent.com.; BioInvent, Lund, Sweden. bjorn.frendeus@bioinvent.com. |
